Scroll for more
news Feb 21, 2017

Bold claims for AI are hard to compute for economists

The Financial Times takes a look at the work we’re doing at BenevolentAI to “revolutionise medical research” after speaking to Co-Founder and Director, Ken Mulvany.

Ken argues that there is an information and data challenge in drug discovery that can be effectively addressed by artificial intelligence (AI). He also describes how we have built a computer “engine” capable of reading and mapping this data, extracting relevant information and highlighting “conceptual hypotheses”. The article also covers our work with researchers at Sheffield University to investigate new pathways to treat motor neurone disease and amyotrophic lateral sclerosis (ALS), stating that “early results are promising”.